Clinical Trial: Evaluation of the efficacy and safety of epaltrakinlimab combined with epirubicin and anlotinib as first-line treatment for unresectabrecurrent or metastatic dedifferentiated liposarcoma: A Phase II clinical study (China)

China, Oct. 22 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Evaluation of the efficacy and safety of epaltrakinlimab combined with epirubicin and anlotinib as first-line treatment for unresectabrecurrent or metastatic dedifferentiated liposarcoma: A Phase II clinical study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134813

Registration Time: 2026/10/21

Type: Interventional study

Primary Sponsor: Zhejiang Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=328746

Published by HT Digital Content Services with permission from Health Daily Digest....